Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
See Why Paul Prescott Has (NASDAQ: BIAF) Up On The Radar Today—Tuesday, June 16, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Quick Look At BIAF While It’s Still Early Enough
In The Day… June 16, 2026
Dear Reader,
Street Ideas is highlighting a biotech story that just jumped to the top of our watchlist this morning.
A molecular diagnostics company trending below $2 with fewer than 5M shares available to the public recently reported 114% year-over-year revenue growth in its latest quarter.
Then came another notable milestone: April sales reached a new company record, with unit sales rising nearly 300% compared to April 2025.
The company has also secured a significant level of institutional support, with the U.S. Department of Defense committing funding for a 2,000-patient multicenter clinical study of its core technology.
That company is bioAffinity Technologies, Inc. (NASDAQ: BIAF), and it's one of the most closely watched names on the Street Ideas radar this morning, Tuesday, June 16, 2026.
But keep in mind, BIAF’s small float could have the potential to witness big moves if demand begins to shift.
And right now, BIAF appears to be flying under the radar while it’s currently trending below $2, according to Barchart.
In fact, the last time we highlighted BIAF, it opened around $1.14 on March 10 and tapped $5.38 on March 23, capping off an approx. 370% move in less than two weeks.
The Clinical Problem: Why Early Lung Cancer Detection Matters
Lung cancer is the most lethal cancer in the United States. It kills nearly 130K Americans annually — more than breast, prostate, and colon cancer combined.
And the primary driver of that staggering death toll is not a treatment problem.
It is a detection problem.
When lung cancer is caught at stage I, the five-year survival rate exceeds 90%.
When it is caught at stage IV — where the majority of patients still receive their first diagnosis — that rate collapses below 10%.
That enormous gap in outcomes is almost entirely a function of when the disease is identified.
The USPSTF recommends annual low-dose CT scans for high-risk individuals — roughly 14M current and former heavy smokers between ages 50 and 80.
But fewer than one in ten eligible adults is actually being screened each year.
The barriers are real: CT requires imaging infrastructure that is not universally accessible, it involves ionizing radiation, and it generates a meaningful rate of false-positive findings that cascade into costly, anxiety-inducing, and sometimes unnecessary invasive follow-up procedures.
The 90%-plus of eligible Americans who are not being screened represent an enormous unmet need — and a substantial market.
bioAffinity Technologies built its entire business model around closing that gap.
What CyPath® Lung Does
CyPath® Lung is a Laboratory Developed Test (LDT) that analyzes sputum — mucus produced deep in the lungs — using flow cytometry and proprietary artificial intelligence.
The test incorporates a fluorescent porphyrin compound (TCPP) that is preferentially absorbed by cancer and cancer-related cells, enabling precise identification of abnormal cell populations from a completely non-invasive sample.
The workflow is straightforward: a high-risk patient provides a sputum sample at home or in a physician's office, ships it to bioAffinity's CLIA-certified laboratory in San Antonio, Texas, and the ordering physician receives a structured risk stratification report within days.
No radiation.
No imaging center.
No invasive procedure of any kind.
In a published, peer-reviewed clinical trial involving high-risk patients with small indeterminate pulmonary nodules under 20 millimeters, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value (NPV).
That 99% NPV is the number we keep returning to at Street Ideas.
In a screening context, a highly reliable negative result is one of the most clinically valuable outputs a diagnostic can deliver — it gives physicians the confidence to defer unnecessary biopsies and avoid the downstream procedural cascade that drives up costs and patient anxiety.
That result changes physician behavior.
Behavioral change in physicians drives reorders, and reorders build a commercial business.
What the Department of Defense Has Committed
The most significant external validation in bioAffinity's history did not come from a hospital partnership or a pharmaceutical licensing deal. It came from the U.S. Department of Defense.
The John P. Murtha Cancer Center Research Program (MCCRP), a DoD research program within the Uniformed Services University of the Health Sciences in Bethesda, Maryland, has committed support and funding for a prospective 2,000-patient longitudinal multicenter clinical study (NCT07168993) to evaluate CyPath® Lung in high-risk patients with pulmonary nodules between 6 and 30 millimeters.
The study expects enrollment at up to 20 clinical sites — including approximately 12 VA medical centers and 2 of the nation's largest military hospitals — with an 18-month enrollment window and up to 24-month patient follow-up.
DoD research programs do not commit to 2,000-patient prospective multicenter trials on unproven science.
The MCCRP peer review process includes scientific, clinical, and consumer reviewers — a rigorous multi-stakeholder evaluation before any funding commitment is made.
When that process produces an institutional commitment at this scale, it carries weight that no company-sponsored press release can replicate.
The downstream strategic implication is not subtle: the Veterans Health Administration serves approximately 9M veterans annually, a population with above-average rates of smoking-related pulmonary disease.
A well-powered, positive dataset from within that system is the most direct pathway to VA system-level adoption discussions imaginable. If this trial delivers, the commercial conversation that follows is a fundamentally different one.
Commercial Momentum That Is Already Visible
In Q1 2026, bioAffinity's CyPath® Lung revenue made a 114% increase year-over-year. In a separate release, the company confirmed that CyPath® Lung unit sales surged 146% year-over-year, while unique physician ordering locations expanded 69% over the prior-year period — meaning the growth is coming from both higher volume in existing accounts and adoption by new physician practices.
Then in April 2026, bioAffinity announced the highest single month of CyPath® Lung sales in company history, with unit sales growing nearly 300% above April 2025. That milestone builds on triple-digit growth across revenue, unit sales, and physician ordering locations, pointing to expanding real-world use and a strengthening commercial foundation for CyPath® Lung.
Near-Term Potential Catalysts
In May 2026, bioAffinity received a patent allowance from Mexico's Instituto Mexicano de la Propiedad Industrial covering novel lung cancer detection methods using CyPath® Lung technology — the company's first international IP expansion, laying legal groundwork for future commercial development in Latin America.
Today, June 16, 2026, a multidisciplinary panel of practicing physicians is presenting real-world CyPath® Lung clinical experience at a Society for Advanced Bronchoscopy webinar. Physicians present in peer settings because they have something substantive to share.
Additionally, bioAffinity launched a 40-patient study at Brooke Army Medical Center evaluating CyPath® Lung technology in patients with asthma and COPD. Positive results would expand the test's addressable indication materially beyond its current lung cancer focus and open a substantially larger total addressable patient population.
The Market Potential
According to Future Market Insights, the global lung cancer diagnostics market is projected to scale from $14.3B in 2026 to reach $29.47B by 2036, growing at a 7.5% compound annual growth rate. In the United States, approximately 14M adults are eligible for annual lung cancer screening under current USPSTF guidelines — and less than 10% of that population is currently being reached.
The unmet need is documented.
The market is growing.
CyPath® Lung is positioned to serve both the unscreened high-risk population and patients with indeterminate CT nodule findings who need a reliable secondary test.
7 Reasons Why BIAF is Topping Our Watchlist Today
—Tuesday, June 16, 2026…
1. Prior Coverage: BIAF previously moved from approximately $1.14 on March 10 to $5.38 on March 23, representing an approximate 370% move in less than two weeks.
2. Small Float: With fewer than 5M shares available to the public, BIAF has a relatively small float that may attract attention from market participants looking for companies with limited share supply. 3. Revenue Surge: BIAF reported CyPath® Lung revenue growth of 114% year-over-year in its most recent quarter, highlighting accelerating commercial traction. 4. Record Sales: BIAF achieved its highest monthly CyPath® Lung sales on record in April 2026, with unit sales climbing nearly 300% compared to April 2025. 5. Clinical Results: BIAF's CyPath® Lung demonstrated 92% sensitivity and a 99% negative predictive value in a published peer-reviewed clinical trial involving high-risk patients. 6. Physician Adoption: BIAF reported a 69% year-over-year increase in unique physician ordering locations alongside 146% growth in CyPath® Lung unit sales. 7. Depart of Defense: BIAF's flagship technology is being evaluated in a Department of Defense-supported 2,000-patient multicenter clinical study spanning VA medical centers and major military hospitals. Take A Quick Look At BIAF While It’s Still Early Enough
In The Day…
BIAF landed on the Street Ideas radar for a reason. See the company's latest corporate presentation here. A float below 5M shares, an approximate 370% move following our prior coverage, triple-digit revenue growth, record sales performance, expanding physician adoption, peer-reviewed clinical results, and a Department of Defense-supported multicenter study have combined to create a story we're watching closely. For now, BIAF remains one of the most interesting names on our watchlist. Pull up BIAF while it's still early in the session and review the latest developments for yourself. As always, stay tuned for my next update—it may be closer than you think. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter |
